Advertisement
Person › Details
Neil Brewis (F-Star Biotechnology Ltd. (F-Star Therapeutics))
Brewis, Neil (F-Star 201611 CSO)
Organisation | F-Star Biotechnology Ltd. (F-Star Therapeutics) | |
Group | Sino Biopharm (Group) | |
Product | mAb2 bispecific antibody platform | |
Product 2 | mAB² antibody (mAb-square) | |
Record changed: 2021-10-22 |
Advertisement
More documents for Neil Brewis
- [1] F-Star Therapeutics Ltd.. (10/20/21). "Press Release: F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics". Cambridge & Cambridge, MA....
- [2] F-Star Biotechnology Ltd.. (3/25/19). "Press Release: F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting". Cambridge....
- [3] F-Star Biotechnology Ltd.. (5/21/18). "Press Release: F-Star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-class Immuno-oncology Bispecific Antibody". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top